A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.

Autor:	Francis OL; Loma Linda University, CA, USA., Milford TA; Loma Linda University, CA, USA., Martinez SR; Loma Linda University, CA, USA., Baez I; Loma Linda University, CA, USA., Coats JS; Loma Linda University, CA, USA., Mayagoitia K; Loma Linda University, CA, USA., Concepcion KR; Loma Linda University, CA, USA., Ginelli E; Loma Linda University, CA, USA., Beldiman C; Loma Linda University, CA, USA., Benitez A; Loma Linda University, CA, USA., Weldon AJ; Loma Linda University, CA, USA., Arogyaswamy K; Loma Linda University, CA, USA., Shiraz P; Loma Linda University, CA, USA., Fisher R; Loma Linda University, CA, USA., Morris CL; Loma Linda University, CA, USA., Zhang XB; Loma Linda University, CA, USA., Filippov V; Loma Linda University, CA, USA., Van Handel B; Novogenix Laboratories, LLC, 1425 San Pablo, CA, USA., Ge Z; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Department of Hematology, Nanjing 210029, China Pennsylvania State University Medical College, Department of Pediatrics, Hershey, PA, USA., Song C; Pennsylvania State University Medical College, Department of Pediatrics, Hershey, PA, USA., Dovat S; Pennsylvania State University Medical College, Department of Pediatrics, Hershey, PA, USA., Su RJ; Loma Linda University, CA, USA., Payne KJ; Loma Linda University, CA, USA kpayne@llu.edu.
Jazyk:	angličtina
Zdroj:	Haematologica [Haematologica] 2016 Apr; Vol. 101 (4), pp. 417-26. Date of Electronic Publication: 2015 Nov 26.
DOI:	10.3324/haematol.2015.125336
Abstrakt:	Thymic stromal lymphopoietin (TSLP) stimulates in-vitro proliferation of human fetal B-cell precursors. However, its in-vivo role during normal human B lymphopoiesis is unknown. Genetic alterations that cause overexpression of its receptor component, cytokine receptor-like factor 2 (CRLF2), lead to high-risk B-cell acute lymphoblastic leukemia implicating this signaling pathway in leukemogenesis. We show that mouse thymic stromal lymphopoietin does not stimulate the downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) activated by the human cytokine in primary high-risk leukemia with overexpression of the receptor component. Thus, the utility of classic patient-derived xenografts for in-vivo studies of this pathway is limited. We engineered xenograft mice to produce human thymic stromal lymphopoietin (+T mice) by injection with stromal cells transduced to express the cytokine. Control (-T) mice were produced using stroma transduced with control vector. Normal levels of human thymic stromal lymphopoietin were achieved in sera of +T mice, but were undetectable in -T mice. Patient-derived xenografts generated from +T as compared to -T mice showed a 3-6-fold increase in normal human B-cell precursors that was maintained through later stages of B-cell development. Gene expression profiles in high-risk B-cell acute lymphoblastic leukemia expanded in +T mice indicate increased mTOR pathway activation and are more similar to the original patient sample than those from -T mice. +T/-T xenografts provide a novel pre-clinical model for understanding this pathway in B lymphopoiesis and identifying treatments for high-risk B-cell acute lymphoblastic leukemia with overexpression of cytokine-like factor receptor 2. (Copyright© Ferrata Storti Foundation.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu